Cached score snapshot

US.RMD · ResMed

110分制 64.1/110;5D動能v2 5/50;排序分 69.1/160 · Incomplete inputs

Ranking score 69.1/160
Main score 64.1/110
5D momentum v2 5/50
Rank #93
Setup grade D 36.4

Score breakdown

觀望

Medium twelvedata

Score and price trend

D 36.4 Money flow A · Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 05-27 07-30 09-01 09-17 10-01 $173.37$223.41$273.44 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.51 · anchors 120 -0.08% -1.89% / +1.46% 47.5% 2.5% Actual +3.57% · vs median +3.65% · inside 25-75 band
30D observation +5.24% +0.59% / +11.30% 77.5% 11.3% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.01% -1.86% / +1.98% 50.6% 2.5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-05-27 → 2026-10-01 · 173 archived points · 3 Improving turn signal · 7 Deteriorating signal · 2 Exit review signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 69.1
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 64.1/110 (觀望)
5D momentum v2 5/50 (弱)
Score with momentum v2 69.1/160 (低排序)
Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Incomplete score

此 snapshot 已計出評分,但以下輸入仍不完整;缺失維度以 0 分處理,請留意 audit 明细。

  • VIX_MISSING: VIX market context is required for market environment scoring

Market inputs

Bar count 60
ma20 218.0105
ma50 206.1808
close 228.44
prevClose 230.65
avgVolume20 1466550
volumeRatio 0.88
changePercent -0.96

Metrics snapshot

close 228.44
volume 1285691
changePercent -0.96

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 64.1/110
Main rating 觀望
5D momentum v2 5/50
Score with momentum v2 69.1/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.3/5 · 優秀

Dimension score 4.3/5
Dimension grade 優秀

Sub-items

pbPoints 0.2
pePoints 0.4
epsPoints 0
roePoints 0.75
debtPoints 0.5
marginPoints 0.75
turnoverUsdM 293.7033
volumePoints 0.5
revenuePoints 0.4
dividendPoints 0.3
marketCapPoints 0.5

資金流 — 15.6/20 · 良好

Dimension score 15.6/20
Dimension grade 良好

Sub-items

cmfPoints 3.2
mfiPoints 4
obvPoints 2.4
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.RMD
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 5.8/15 · 較差

Dimension score 5.8/15
Dimension grade 較差

Sub-items

vix

score 0

details

source twelvedata+fred
missing true
vixClose n/a

trend

score 3

details

qqq

ma20 707.728
ma50 713.0466
name QQQ
close 710.93
points 1

spy

ma20 760.9875
ma50 750.9438
name SPY
close 762.6
points 2
source twelvedata+fred
atrPct 3.457
atrPoints 2
cciPoints 0.8
vixPoints 0
marketTrendPoints 3

催化劑 — 6/20 · 較差

Dimension score 6/20
Dimension grade 較差

Sub-items

catalyst

score 6

details

source finnhub_news_keyword_model
articleCount 8
catalystCount 1
catalystPoints 6

風險管理 — 6.7/10 · 一般

Dimension score 6.7/10
Dimension grade 一般

Sub-items

position

score 1.3

details

atrPct 3.457
turnoverUsdM 293.7033
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.6

stopLevels

symbol US.RMD
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 212.6458

strength_details

ma_score 1.5
atr_score 1
rsi_score 3
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.5
stop_loss_percent 6.9
take_profit_price 251.6048
target_multiplier 2.2
technical_strength 2
take_profit_percent 10.1
positionPoints 1.3
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.4608
stopLossPercent 6.9139
diversificationPoints 2

技術信號 — 21.7/30 · 良好

Dimension score 21.7/30
Dimension grade 良好

Sub-items

bbPoints 3
adxPoints 3
sarPoints 2.4
vcpPoints 0.4
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 0.4
vcp_reason 站上MA50;Ready=N;Confirm=N

vcp_metrics

up_days 5
vol_ref 1409496.6667
down_days 4
vcp_ready false
above_ma50 true
avg_vol_10 1627490
avg_vol_20 1452890
avg_vol_30 1409496.6667
range_pct_10 0.1271
range_pct_20 0.1787
range_pct_30 0.1787
up_expand_ok false
lookback_used 59
near_20d_high true
contraction_ok false
down_shrink_ok false
up_expand_days 1
breakout_20d_ok false
vol_ratio_10_30 1.1547
dist_to_20d_high 0.0113
down_shrink_days 2
breakout_level_20d 231.04
vcp_breakout_confirm false
contraction_ratio_10_30 0.7112
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction false
kdjAdxPoints 0.7
rsiKdjPoints 4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.8
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 4/10 · 較差

Dimension score 4/10
Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model
articleCount 8
negativeHits 0
positiveHits 2
sentimentScoreRaw 0.6

sentimentData

raw {"id":141259118,"url":"https://finnhub.io/api/news?id=a4f03eaf20b67dad07870e03380efd8a674caf30e00758efdf24378602e63067","image":"","source":"Fintel","related":"RMD","summary":"","category":"company","datetime":1787196494,"headline":"Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation"}, {"id":141202371,"url":"https://finnhub.io/api/news?id=a14265c9592c375e48e5eb528b975618d736e006f258f344b092ca3a052a5fc6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...","category":"company","datetime":1786529545,"headline":"ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook"}, {"id":141202372,"url":"https://finnhub.io/api/news?id=ac834b7859cf4b846702996dda6c6e37f63e3abb547173b38d11e3b8ddae9292","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...","category":"company","datetime":1786502030,"headline":"Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?"}, {"id":141172251,"url":"https://finnhub.io/api/news?id=f2063936d03cb19961ca791af5534a8c650f80d3788699052506252a8fba69ac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.","category":"company","datetime":1786340002,"headline":"RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts"}, {"id":141149640,"url":"https://finnhub.io/api/news?id=9330c5d081238104a84cc1a9ddf25b5c9eb1eb96172fe7a4c6eb81db3d1c6b84","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.","category":"company","datetime":1786115520,"headline":"RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y"}, {"id":141144733,"url":"https://finnhub.io/api/news?id=e26f47ae823ecc252f5680e158079bb8a60f3037a644a23f92ff40536cfbfebf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed Inc (RMD) delivers 9% revenue growth and 16% EPS growth in Q4 FY2026, while navigating Astral-related challenges and guiding to 5-7% core growth for FY2027.","category":"company","datetime":1786079567,"headline":"ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ..."}, {"id":141143188,"url":"https://finnhub.io/api/news?id=07e7ea94ce7a8f216624befb92fb3e600fa186c7ba568ef257a838dec6539b5e","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RMD","summary":"ResMed Inc. (RMD) Q4 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsSallilyn Schwartz - Chief Investor Relations OfficerMichael Farrell -...","category":"company","datetime":1786053258,"headline":"ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript"}, {"id":141142416,"url":"https://finnhub.io/api/news?id=6f2d99ac4b464c82a818cf0692813ffcce8906c93fba111d3986dafdfc43bc5c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.","category":"company","datetime":1786052824,"headline":"ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops"}
raw_source {"id":141259118,"url":"https://finnhub.io/api/news?id=a4f03eaf20b67dad07870e03380efd8a674caf30e00758efdf24378602e63067","image":"","source":"Fintel","related":"RMD","summary":"","category":"company","datetime":1787196494,"headline":"Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation"}, {"id":141256632,"url":"https://finnhub.io/api/news?id=fd6b4b9263365d5e722887f53950c3a77f3efafa38fb8a58e4e469ccdde30b51","image":"","source":"Benzinga","related":"RMD","summary":"Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.","category":"company","datetime":1787136422,"headline":"Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230"}, {"id":141231506,"url":"https://finnhub.io/api/news?id=9d892d1c46fc34e76484400133ccfacd3aaf49d29a7d83b06d9eef6c6da6ce1f","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1562199023/image_1562199023.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"RMD","summary":"Weekly dividend stock updates: 21 hikes, 1 cut, 1 special. See top picks BR, CSL & RMD—quality, safety and undervaluation.","category":"company","datetime":1786873045,"headline":"Dividend Announcements: August 1-7, 2026"}, {"id":141220362,"url":"https://finnhub.io/api/news?id=aca754d054c2cc29e122e29d60fc10d0d806a9a9424655c9d9e085ef4de25d34","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"RMD","summary":"Weekly dividend summary for Dividend Champions, Contenders & Challengers—read the full list of dividend changes, upcoming ex-dividend dates and pay dates here.","category":"company","datetime":1786730477,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week August 16"}, {"id":141192693,"url":"https://finnhub.io/api/news?id=1a51c3fda625137f05bd7a8622dd3db9cd4f97aa3ff563d6f1aa5511d9562da4","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"RMD","summary":"As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.","category":"company","datetime":1786538101,"headline":"Which S&P500 stocks are moving before the opening bell on Wednesday?"}, {"id":141202371,"url":"https://finnhub.io/api/news?id=a14265c9592c375e48e5eb528b975618d736e006f258f344b092ca3a052a5fc6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...","category":"company","datetime":1786529545,"headline":"ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook"}, {"id":141202372,"url":"https://finnhub.io/api/news?id=ac834b7859cf4b846702996dda6c6e37f63e3abb547173b38d11e3b8ddae9292","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...","category":"company","datetime":1786502030,"headline":"Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?"}, {"id":141202373,"url":"https://finnhub.io/api/news?id=7c4506bd336d7052bb2aa2945f9f087fdc744710d9111a84d3688d4b0a575537","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.","category":"company","datetime":1786465380,"headline":"Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists"}, {"id":141202374,"url":"https://finnhub.io/api/news?id=c9a55f0c358b934750870cb43810aa47c1355f539cbb188366e6b5733580ef3c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.","category":"company","datetime":1786465320,"headline":"Should Investors Buy Inogen as Low Valuation Meets Execution Risk?"}, {"id":141173748,"url":"https://finnhub.io/api/news?id=36ece7701581afbc0c45cf4c64a289371a52775d64bb8b21d154e5aa1ad1a304","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.","category":"company","datetime":1786360137,"headline":"Resmed’s stock falls by 7% on soft FY27 outlook"}, {"id":141172251,"url":"https://finnhub.io/api/news?id=f2063936d03cb19961ca791af5534a8c650f80d3788699052506252a8fba69ac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.","category":"company","datetime":1786340002,"headline":"RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts"}, {"id":141164496,"url":"https://finnhub.io/api/news?id=a45c6768cb0a925167bb2caabc3e4fdcc136f4362e935257ea82e41483442ced","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electroni","category":"company","datetime":1786248229,"headline":"ResMed Q4 Earnings Call Highlights"}, {"id":141164828,"url":"https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"RMD","summary":"I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.","category":"company","datetime":1786243803,"headline":"Top 50 High-Quality Dividend Growth Stocks For August 2026"}, {"id":141150616,"url":"https://finnhub.io/api/news?id=97cc30b60f13c7af214f0c0afb17997cc515ad12a36ad63fdf4d3ec954ca3f5c","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RMD","summary":"Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.","category":"company","datetime":1786129501,"headline":"Stay informed with the top movers within the S&P500 index on Friday."}, {"id":141152423,"url":"https://finnhub.io/api/news?id=af72a397d825898b459a1a054ad11e152f22a3d67f610472c2aab599efe41d41","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"RMD","summary":"Weekly dividend activity roundup for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.","category":"company","datetime":1786125278,"headline":"Dividend Champion, Contender, And Challenger Highlights: Week Of August 9"}, {"id":141149003,"url":"https://finnhub.io/api/news?id=ef9e2796d2ec153c86f76a0efc5f8a7f4a4eab218d749fcd6a3713e33e419366","image":"https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp","source":"ChartMill","related":"RMD","summary":"In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Friday's session.","category":"company","datetime":1786122300,"headline":"In today's session, there are S&P500 stocks with remarkable trading volume."}, {"id":141148910,"url":"https://finnhub.io/api/news?id=9bdba43fcab22b2cbe6b2e92788d4e69dd55e6b163385f9dbbc531c0004beafd","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RMD","summary":"Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.","category":"company","datetime":1786120501,"headline":"Top S&P500 movers in Friday's session"}, {"id":141153610,"url":"https://finnhub.io/api/news?id=162e6edef4356f7eb0c7235270c0972716ca4d6de76862bbf7006d9764dc6d8b","image":"","source":"Benzinga","related":"RMD","summary":"RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.","category":"company","datetime":1786119093,"headline":"RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244"}, {"id":141149640,"url":"https://finnhub.io/api/news?id=9330c5d081238104a84cc1a9ddf25b5c9eb1eb96172fe7a4c6eb81db3d1c6b84","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.","category":"company","datetime":1786115520,"headline":"RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y"}, {"id":141147567,"url":"https://finnhub.io/api/news?id=ba7e0c36628e3e622f779f9a6b4fcefb13ededca266f41f5382d1d7a360c7967","image":"https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp","source":"ChartMill","related":"RMD","summary":"Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.","category":"company","datetime":1786113301,"headline":"What's going on in today's session: S&P500 gap up and gap down stocks"}, {"id":141149831,"url":"https://finnhub.io/api/news?id=ed83215398feaf5df6a377a600ecc89fd18ace8239fcbfea60c662d7e787cdcb","image":"https://cdn.benzinga.com/files/images/story/2026/08/07/SP-500.jpg?width=2048&height=1536","source":"Benzinga","related":"RMD","summary":"U.S. payrolls fell 23,000 in July, gutting September Fed hike odds. The S&P 500 hit a record, while gold jumped to a seven-week high.","category":"company","datetime":1786109247,"headline":"S&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today"}, {"id":141153612,"url":"https://finnhub.io/api/news?id=e1469dc4cf1a9b93443bc8bde6236da05ac919be746cb5a96c540e9b8973bcff","image":"","source":"Benzinga","related":"RMD","summary":"Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.","category":"company","datetime":1786108086,"headline":"Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225"}, {"id":141147080,"url":"https://finnhub.io/api/news?id=fb38d0e669c6ebb7a77e00e1f4b64b1991a2b958d779c41b6078dc5f53e51b92","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"(Updates with economic data, recent oil price movement, world markets' overview and corporate stock","category":"company","datetime":1786107416,"headline":"Update: US Equity Futures Rise Pre-Bell as Traders Assess Jobs Report, Monitor Middle East Developments"}, {"id":141147229,"url":"https://finnhub.io/api/news?id=f5260272055fee7d9ab541f25d669d7f9cdde5e74466a245840c9fcc7e6a19f1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed (NYSE:RMD) shares declined 5. 5% in premarket trading after the medical device manufacturer reported fourth-quarter fiscal 2026 results that delivered an earnings beat but fell slightly short on revenue.","category":"company","datetime":1786106465,"headline":"ResMed Shares Fall After Revenue Miss and Conservative 2027 Outlook"}, {"id":141146666,"url":"https://finnhub.io/api/news?id=073c54ac6a5c9a52cf67af390cc14433ee433ae80c98f88141a2bf1f9b5787c4","image":"https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp","source":"ChartMill","related":"RMD","summary":"Before the opening bell on Friday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.","category":"company","datetime":1786106101,"headline":"Which S&P500 stocks are moving before the opening bell on Friday?"}, {"id":141153613,"url":"https://finnhub.io/api/news?id=f42af4e01184cab1b7ec516f2215779f322997ffc7c5035bf6917b5b9f0241e5","image":"","source":"Benzinga","related":"RMD","summary":"Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.","category":"company","datetime":1786097629,"headline":"Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255"}, {"id":141153614,"url":"https://finnhub.io/api/news?id=819e2b995fef2a78d1d9a608be1176eeb6975e3f90ffc8bd6d66e62a7b120924","image":"","source":"Benzinga","related":"RMD","summary":"Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.","category":"company","datetime":1786097490,"headline":"Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215"}, {"id":141147448,"url":"https://finnhub.io/api/news?id=42771496d59a56028a962cf7d3e7928c840ba00554b95a93a821fabde9142024","image":"https://cdn.benzinga.com/files/images/story/2026/08/07/Portland--Or--Usa---Jan-21--2021-The-Tra.jpg?width=2048&height=1536","source":"Benzinga","related":"RMD","summary":"US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.","category":"company","datetime":1786089735,"headline":"Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session"}, {"id":141144733,"url":"https://finnhub.io/api/news?id=e26f47ae823ecc252f5680e158079bb8a60f3037a644a23f92ff40536cfbfebf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed Inc (RMD) delivers 9% revenue growth and 16% EPS growth in Q4 FY2026, while navigating Astral-related challenges and guiding to 5-7% core growth for FY2027.","category":"company","datetime":1786079567,"headline":"ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ..."}, {"id":141143188,"url":"https://finnhub.io/api/news?id=07e7ea94ce7a8f216624befb92fb3e600fa186c7ba568ef257a838dec6539b5e","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RMD","summary":"ResMed Inc. (RMD) Q4 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsSallilyn Schwartz - Chief Investor Relations OfficerMichael Farrell -...","category":"company","datetime":1786053258,"headline":"ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript"}, {"id":141142416,"url":"https://finnhub.io/api/news?id=6f2d99ac4b464c82a818cf0692813ffcce8906c93fba111d3986dafdfc43bc5c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.","category":"company","datetime":1786052824,"headline":"ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops"}, {"id":141142417,"url":"https://finnhub.io/api/news?id=f9835639451fee0e6b3630315db2f0c70a6a253a6d8916bc5d7a11ff366e728e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed (RMD) delivered earnings and revenue surprises of +1.72% and +0.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1786052409,"headline":"ResMed (RMD) Q4 Earnings and Revenues Top Estimates"}, {"id":141142998,"url":"https://finnhub.io/api/news?id=e266785fa8d8f2d00504ae73786d8ead1e0a5b1add3451405a963a5df2d9e061","image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","source":"SeekingAlpha","related":"RMD","summary":"2026-08-06. The following slide deck was published by ResMed Inc.","category":"company","datetime":1786051868,"headline":"ResMed Inc. 2026 Q4 - Results - Earnings Call Presentation"}, {"id":141139799,"url":"https://finnhub.io/api/news?id=3c4e732c0a08f2d876c2a482f4d79b93814f8d2b83bdda5964d532f85e4bc1a0","image":"https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp","source":"ChartMill","related":"RMD","summary":"ResMed (RMD) Q4 revenue slightly misses, EPS beats; stock dips ~2% on profit-taking despite record results and raised dividend.","category":"company","datetime":1786050938,"headline":"ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9%"}, {"id":141140799,"url":"https://finnhub.io/api/news?id=e661e2a1607bf2ad8fcb76dbef26ff8284d18411bf61d9c0b7cc5f4dc1110ed7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70% Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX:","category":"company","datetime":1786046700,"headline":"Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026"}, {"id":141141984,"url":"https://finnhub.io/api/news?id=5ff0d18d32d01d3f09f4fc144fb8aa27a500d0047f05ed5443dde9968e6c51ad","image":"","source":"Benzinga","related":"RMD","summary":"ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share from the same period","category":"company","datetime":1786032357,"headline":"ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate"}, {"id":141134279,"url":"https://finnhub.io/api/news?id=24ccbb918500a4321fa00cad22c2de330360be3abbadfb067d8963d2611deb98","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Why the upcoming ResMed earnings matter ResMed (RMD) is back in focus ahead of its forthcoming earnings report, with Wall Street projecting quarterly earnings of $2.90 per share and revenue of about $1.46b for the period. See our latest analysis for ResMed. ResMed shares have climbed in recent weeks, with a 7 day share price return of 4.55% and a 90 day share price return of 8.28%. However, the year to date share price return is still down 8.49%, and the 1 year total shareholder return has...","category":"company","datetime":1786022182,"headline":"ResMed (RMD) Faces An Earnings Test After A Rebound That Still Looks Undervalued"}, {"id":141125710,"url":"https://finnhub.io/api/news?id=908443464c6dac93d7d144bad74f909237b4d1ce507acfbe554ffe8dd66c08d9","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.","category":"company","datetime":1785952740,"headline":"Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?"}, {"id":141125711,"url":"https://finnhub.io/api/news?id=86654da613505d37a72deed55f1f4b51cbc7a004fc7b41b9e6fd5f1e19cb0c5a","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.","category":"company","datetime":1785951300,"headline":"INSP's 28.1% Past-Month Rally Raises a Key Question for Investors"}, {"id":141122934,"url":"https://finnhub.io/api/news?id=5ebdc3970abbb2a2338a21c3afa648199e0f3a8e8c03b36dd04d8ac65b339e0d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.","category":"company","datetime":1785941820,"headline":"What to Expect From These 2 MedTech Stocks This Earnings Season?"}, {"id":141122755,"url":"https://finnhub.io/api/news?id=679dc62b0d6341e0716993d69a4659ffa37cff052797d6fbc10f1828108e701d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.","category":"company","datetime":1785935706,"headline":"Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics"}, {"id":141104327,"url":"https://finnhub.io/api/news?id=352cc05ac2d4a26c5635f6fdf97bc1040f7f84f82a959edb3181f428a871c81d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Viemed Healthcare (VMD) delivered earnings and revenue surprises of -30.00% and +0.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785797109,"headline":"Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates"}, {"id":141103236,"url":"https://finnhub.io/api/news?id=124e694ad0b3e2f69b544333b87c4d5251ef48d8bf142f9f9ca9f8ba16d24cdb","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.","category":"company","datetime":1785788962,"headline":"1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky"}, {"id":141079192,"url":"https://finnhub.io/api/news?id=ba7731a4b95a73e9b539fb9155adffe31e1dea22943a4c45be8f8fa12e57990b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.","category":"company","datetime":1785504720,"headline":"Resmed's Q4 Earnings on Deck: What's in Store for the Stock?"}, {"id":141078062,"url":"https://finnhub.io/api/news?id=eccab60418f61c40d3a156f57c0957bf7084f81ce29971339390e78da2a7b84d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.","category":"company","datetime":1785504709,"headline":"3 Large-Cap Stocks to Consider Right Now"}, {"id":141067141,"url":"https://finnhub.io/api/news?id=2eba5c1a1a25c1b0f492d696ae339d2d6665a3f0234260cb85aab3bb8fd081ad","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","category":"company","datetime":1785420019,"headline":"ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth"}, {"id":141065678,"url":"https://finnhub.io/api/news?id=627351a5866f253bd786f5ad7587b3fed6c6ee8ec3bbe68f04ebc325dd60a5ac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"Baxter (BAX) delivered earnings and revenue surprises of +55.56% and +5.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?","category":"company","datetime":1785414903,"headline":"Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates"}, {"id":140991410,"url":"https://finnhub.io/api/news?id=a7d3773d8f60001c539390370a53abf66180cc30e499445d40c79aec749bde17","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital.","category":"company","datetime":1784791489,"headline":"3 Cash-Heavy Stocks to Research Further"}, {"id":140973578,"url":"https://finnhub.io/api/news?id=d1da9496c35a7b3d8bb71682a817d89804339dc66aec5bf1446d9a2e13a70166","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RMD","summary":"ResMed (RMD) is expected to post strong fiscal Q4 earnings growth, helped by an 8.6% rise in sales a","category":"company","datetime":1784653509,"headline":"ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says"}
data_source finnhub_news_keyword_model
article_count 8
negative_hits 0
positive_hits 2
recomputed_at_score true
sentiment_score_raw 0.6
source_article_count 49
discarded_article_count 36
sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 4.3 5/110 86% 4.3
資金流 15.6 20/110 78% 15.6
市場環境 5.8 15/110 38.67% 5.8
催化劑 6 20/110 30% 6
風險管理 6.7 10/110 67% 6.7
技術信號 21.7 30/110 72.33% 21.7
情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 5/50
ret_5d 0.0075
max_score 50
max_total 50
raw_total 5
vcp_bonus 0
vol_ratio 0.8849
ret_points 4
vol_points 0
range_ratio 0.653
volat_points 0
day_range_pct 0.02
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 1
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Medium
reason risk management score >= 6.5/10

position

score 1.3

details

atrPct 3.457
turnoverUsdM 293.7033
liquidityPoints 0.6
volatilityPoints 0.7
rrPoints 1.6

stopLevels

symbol US.RMD
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 212.6458

strength_details

ma_score 1.5
atr_score 1
rsi_score 3
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1.5
stop_loss_percent 6.9
take_profit_price 251.6048
target_multiplier 2.2
technical_strength 2
take_profit_percent 10.1
positionPoints 1.3
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.4608
stopLossPercent 6.9139
diversificationPoints 2

Calculation audit log

基本面分析總分: 4.3/5分
資金流分析總分: 15.6/20分
市場環境分析總分: 5.8/15分
催化劑分析: 6/20分
風險管理總分: 6.7/10分
技術信號分析總分: 21.7/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 92.86
atr
atr 7.8971
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.46
cci
rule Cursor_18.24 CCI bands
level 超買或超賣風險
score 2
value 113.63
cmf
rule Cursor_18.24 CMF bands
level 資金流入
score 8
value 0.2792
kdj
d 82.73
j 82.76
k 82.74
rule Cursor_18.24 K/D cross
score 4
signal 金叉
mfi
rule Cursor_18.24 MFI bands
level 強資金流入
score 10
value 71.97
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 6
trend 有流入
value 3383409
recentSlope 150700.9
previousSlope 298640
rsi
value 64.65
sar
rule Cursor_18.24 Parabolic SAR
score 8
trend 上升
value 220.9229
position SAR喺價下
distancePct 3.29
previousTrend 上升
ma50
value 206.1808
macd
macd 6.2112
trend 強烈看漲
signal 5.7387
histogram 0.4725
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 216.9934
position 連續5日>VWAP
consecutiveAbove 19
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.88
score 4
avgVolume 1466550
currentVolume 1285691
derived
ma20 218.0105
ma50 206.1808
prevClose 230.65
avgVolume10 1577449
avgVolume20 1466550
changePercent -0.96
avgVolumeForScore 1466550
ma_cross
ma20 218.0105
ma50 206.1808
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 216.183
prevMa50 205.5508
spreadPct 5.74
isVolumeBreakout false
bollinger
lower 200.0124
upper 236.0086
position 上半部
rsi_short
value 55.99
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.88

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.4569690071791284,
        "turnoverUsdM": 293.70325204,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.6,
    "stopLevels": {
      "symbol": "US.RMD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 212.6458,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.5,
      "stop_loss_percent": 6.9,
      "take_profit_price": 251.6048,
      "target_multiplier": 2.2,
      "technical_strength": 2,
      "take_profit_percent": 10.1
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.4608172620328979,
    "stopLossPercent": 6.913938014358257,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 69.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 64.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 5
  },
  "market": {
    "ma20": 218.0105,
    "ma50": 206.1808,
    "close": 228.44,
    "prevClose": 230.65,
    "avgVolume20": 1466550,
    "volumeRatio": 0.88,
    "changePercent": -0.96
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 5,
    "details": {
      "ret_5d": 0.007497529880147624,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 5,
      "vcp_bonus": 0,
      "vol_ratio": 0.884919711746932,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.6530234232127959,
      "volat_points": 0,
      "day_range_pct": 0.02000529679565761,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 69.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 86,
        "contribution": 4.3
      },
      {
        "raw": 15.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 78,
        "contribution": 15.6
      },
      {
        "raw": 5.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 38.67,
        "contribution": 5.8
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 6.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 67,
        "contribution": 6.7
      },
      {
        "raw": 21.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 72.33,
        "contribution": 21.7
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 64.1,
    "details": [
      "基本面分析總分: 4.3/5分",
      "資金流分析總分: 15.6/20分",
      "市場環境分析總分: 5.8/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 6.7/10分",
      "技術信號分析總分: 21.7/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4.3,
      "資金流": 15.6,
      "市場環境": 5.8,
      "情緒分析": 4,
      "技術信號": 21.7,
      "風險管理": 6.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 293.70325204,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 4,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.RMD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 707.7280003500002,
                "ma50": 713.0466018399998,
                "name": "QQQ",
                "close": 710.92999,
                "points": 1
              },
              "spy": {
                "ma20": 760.98750315,
                "ma50": 750.9438048,
                "name": "SPY",
                "close": 762.59998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.4569690071791284,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141259118,
                "url": "https://finnhub.io/api/news?id=a4f03eaf20b67dad07870e03380efd8a674caf30e00758efdf24378602e63067",
                "image": "",
                "source": "Fintel",
                "related": "RMD",
                "summary": "",
                "category": "company",
                "datetime": 1787196494,
                "headline": "Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation"
              },
              {
                "id": 141202371,
                "url": "https://finnhub.io/api/news?id=a14265c9592c375e48e5eb528b975618d736e006f258f344b092ca3a052a5fc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...",
                "category": "company",
                "datetime": 1786529545,
                "headline": "ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook"
              },
              {
                "id": 141202372,
                "url": "https://finnhub.io/api/news?id=ac834b7859cf4b846702996dda6c6e37f63e3abb547173b38d11e3b8ddae9292",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...",
                "category": "company",
                "datetime": 1786502030,
                "headline": "Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?"
              },
              {
                "id": 141172251,
                "url": "https://finnhub.io/api/news?id=f2063936d03cb19961ca791af5534a8c650f80d3788699052506252a8fba69ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786340002,
                "headline": "RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts"
              },
              {
                "id": 141149640,
                "url": "https://finnhub.io/api/news?id=9330c5d081238104a84cc1a9ddf25b5c9eb1eb96172fe7a4c6eb81db3d1c6b84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.",
                "category": "company",
                "datetime": 1786115520,
                "headline": "RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y"
              },
              {
                "id": 141144733,
                "url": "https://finnhub.io/api/news?id=e26f47ae823ecc252f5680e158079bb8a60f3037a644a23f92ff40536cfbfebf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed Inc (RMD) delivers 9% revenue growth and 16% EPS growth in Q4 FY2026, while navigating Astral-related challenges and guiding to 5-7% core growth for FY2027.",
                "category": "company",
                "datetime": 1786079567,
                "headline": "ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ..."
              },
              {
                "id": 141143188,
                "url": "https://finnhub.io/api/news?id=07e7ea94ce7a8f216624befb92fb3e600fa186c7ba568ef257a838dec6539b5e",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "ResMed Inc. (RMD) Q4 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsSallilyn Schwartz - Chief Investor Relations OfficerMichael Farrell -...",
                "category": "company",
                "datetime": 1786053258,
                "headline": "ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript"
              },
              {
                "id": 141142416,
                "url": "https://finnhub.io/api/news?id=6f2d99ac4b464c82a818cf0692813ffcce8906c93fba111d3986dafdfc43bc5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786052824,
                "headline": "ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops"
              }
            ],
            "raw_source": [
              {
                "id": 141259118,
                "url": "https://finnhub.io/api/news?id=a4f03eaf20b67dad07870e03380efd8a674caf30e00758efdf24378602e63067",
                "image": "",
                "source": "Fintel",
                "related": "RMD",
                "summary": "",
                "category": "company",
                "datetime": 1787196494,
                "headline": "Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation"
              },
              {
                "id": 141256632,
                "url": "https://finnhub.io/api/news?id=fd6b4b9263365d5e722887f53950c3a77f3efafa38fb8a58e4e469ccdde30b51",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "Rothschild & Co  analyst Jackson Philips   initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.",
                "category": "company",
                "datetime": 1787136422,
                "headline": "Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230"
              },
              {
                "id": 141231506,
                "url": "https://finnhub.io/api/news?id=9d892d1c46fc34e76484400133ccfacd3aaf49d29a7d83b06d9eef6c6da6ce1f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1562199023/image_1562199023.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "Weekly dividend stock updates: 21 hikes, 1 cut, 1 special. See top picks BR, CSL & RMD—quality, safety and undervaluation.",
                "category": "company",
                "datetime": 1786873045,
                "headline": "Dividend Announcements: August 1-7, 2026"
              },
              {
                "id": 141220362,
                "url": "https://finnhub.io/api/news?id=aca754d054c2cc29e122e29d60fc10d0d806a9a9424655c9d9e085ef4de25d34",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "Weekly dividend summary for Dividend Champions, Contenders & Challengers—read the full list of dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786730477,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 16"
              },
              {
                "id": 141192693,
                "url": "https://finnhub.io/api/news?id=1a51c3fda625137f05bd7a8622dd3db9cd4f97aa3ff563d6f1aa5511d9562da4",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.",
                "category": "company",
                "datetime": 1786538101,
                "headline": "Which S&P500 stocks are moving before the opening bell on Wednesday?"
              },
              {
                "id": 141202371,
                "url": "https://finnhub.io/api/news?id=a14265c9592c375e48e5eb528b975618d736e006f258f344b092ca3a052a5fc6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...",
                "category": "company",
                "datetime": 1786529545,
                "headline": "ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook"
              },
              {
                "id": 141202372,
                "url": "https://finnhub.io/api/news?id=ac834b7859cf4b846702996dda6c6e37f63e3abb547173b38d11e3b8ddae9292",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...",
                "category": "company",
                "datetime": 1786502030,
                "headline": "Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?"
              },
              {
                "id": 141202373,
                "url": "https://finnhub.io/api/news?id=7c4506bd336d7052bb2aa2945f9f087fdc744710d9111a84d3688d4b0a575537",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.",
                "category": "company",
                "datetime": 1786465380,
                "headline": "Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists"
              },
              {
                "id": 141202374,
                "url": "https://finnhub.io/api/news?id=c9a55f0c358b934750870cb43810aa47c1355f539cbb188366e6b5733580ef3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.",
                "category": "company",
                "datetime": 1786465320,
                "headline": "Should Investors Buy Inogen as Low Valuation Meets Execution Risk?"
              },
              {
                "id": 141173748,
                "url": "https://finnhub.io/api/news?id=36ece7701581afbc0c45cf4c64a289371a52775d64bb8b21d154e5aa1ad1a304",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.",
                "category": "company",
                "datetime": 1786360137,
                "headline": "Resmed’s stock falls by 7% on soft FY27 outlook"
              },
              {
                "id": 141172251,
                "url": "https://finnhub.io/api/news?id=f2063936d03cb19961ca791af5534a8c650f80d3788699052506252a8fba69ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786340002,
                "headline": "RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts"
              },
              {
                "id": 141164496,
                "url": "https://finnhub.io/api/news?id=a45c6768cb0a925167bb2caabc3e4fdcc136f4362e935257ea82e41483442ced",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electroni",
                "category": "company",
                "datetime": 1786248229,
                "headline": "ResMed Q4 Earnings Call Highlights"
              },
              {
                "id": 141164828,
                "url": "https://finnhub.io/api/news?id=67a12f998d09e3a8032fc7543984727ae385b02a09472666c7971ce61d490975",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. Check out the list here.",
                "category": "company",
                "datetime": 1786243803,
                "headline": "Top 50 High-Quality Dividend Growth Stocks For August 2026"
              },
              {
                "id": 141150616,
                "url": "https://finnhub.io/api/news?id=97cc30b60f13c7af214f0c0afb17997cc515ad12a36ad63fdf4d3ec954ca3f5c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1786129501,
                "headline": "Stay informed with the top movers within the S&P500 index on Friday."
              },
              {
                "id": 141152423,
                "url": "https://finnhub.io/api/news?id=af72a397d825898b459a1a054ad11e152f22a3d67f610472c2aab599efe41d41",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "Weekly dividend activity roundup for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.",
                "category": "company",
                "datetime": 1786125278,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 9"
              },
              {
                "id": 141149003,
                "url": "https://finnhub.io/api/news?id=ef9e2796d2ec153c86f76a0efc5f8a7f4a4eab218d749fcd6a3713e33e419366",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Friday's session.",
                "category": "company",
                "datetime": 1786122300,
                "headline": "In today's session, there are S&P500 stocks with remarkable trading volume."
              },
              {
                "id": 141148910,
                "url": "https://finnhub.io/api/news?id=9bdba43fcab22b2cbe6b2e92788d4e69dd55e6b163385f9dbbc531c0004beafd",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.",
                "category": "company",
                "datetime": 1786120501,
                "headline": "Top S&P500 movers in Friday's session"
              },
              {
                "id": 141153610,
                "url": "https://finnhub.io/api/news?id=162e6edef4356f7eb0c7235270c0972716ca4d6de76862bbf7006d9764dc6d8b",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "RBC Capital  analyst Craig Wong-Pan   maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.",
                "category": "company",
                "datetime": 1786119093,
                "headline": "RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244"
              },
              {
                "id": 141149640,
                "url": "https://finnhub.io/api/news?id=9330c5d081238104a84cc1a9ddf25b5c9eb1eb96172fe7a4c6eb81db3d1c6b84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.",
                "category": "company",
                "datetime": 1786115520,
                "headline": "RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y"
              },
              {
                "id": 141147567,
                "url": "https://finnhub.io/api/news?id=ba7e0c36628e3e622f779f9a6b4fcefb13ededca266f41f5382d1d7a360c7967",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1786113301,
                "headline": "What's going on in today's session: S&P500 gap up and gap down stocks"
              },
              {
                "id": 141149831,
                "url": "https://finnhub.io/api/news?id=ed83215398feaf5df6a377a600ecc89fd18ace8239fcbfea60c662d7e787cdcb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/07/SP-500.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "U.S. payrolls fell 23,000 in July, gutting September Fed hike odds. The S&P 500 hit a record, while gold jumped to a seven-week high.",
                "category": "company",
                "datetime": 1786109247,
                "headline": "S&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today"
              },
              {
                "id": 141153612,
                "url": "https://finnhub.io/api/news?id=e1469dc4cf1a9b93443bc8bde6236da05ac919be746cb5a96c540e9b8973bcff",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "Piper Sandler  analyst Adam Maeder   maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.",
                "category": "company",
                "datetime": 1786108086,
                "headline": "Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225"
              },
              {
                "id": 141147080,
                "url": "https://finnhub.io/api/news?id=fb38d0e669c6ebb7a77e00e1f4b64b1991a2b958d779c41b6078dc5f53e51b92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "(Updates with economic data, recent oil price movement, world markets' overview and corporate stock",
                "category": "company",
                "datetime": 1786107416,
                "headline": "Update: US Equity Futures Rise Pre-Bell as Traders Assess Jobs Report, Monitor Middle East Developments"
              },
              {
                "id": 141147229,
                "url": "https://finnhub.io/api/news?id=f5260272055fee7d9ab541f25d669d7f9cdde5e74466a245840c9fcc7e6a19f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed (NYSE:RMD) shares declined 5. 5% in premarket trading after the medical device manufacturer reported fourth-quarter fiscal 2026 results that delivered an earnings beat but fell slightly short on revenue.",
                "category": "company",
                "datetime": 1786106465,
                "headline": "ResMed Shares Fall After Revenue Miss and Conservative 2027 Outlook"
              },
              {
                "id": 141146666,
                "url": "https://finnhub.io/api/news?id=073c54ac6a5c9a52cf67af390cc14433ee433ae80c98f88141a2bf1f9b5787c4",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "Before the opening bell on Friday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.",
                "category": "company",
                "datetime": 1786106101,
                "headline": "Which S&P500 stocks are moving before the opening bell on Friday?"
              },
              {
                "id": 141153613,
                "url": "https://finnhub.io/api/news?id=f42af4e01184cab1b7ec516f2215779f322997ffc7c5035bf6917b5b9f0241e5",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "Keybanc  analyst Brett Fishbin   maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.",
                "category": "company",
                "datetime": 1786097629,
                "headline": "Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255"
              },
              {
                "id": 141153614,
                "url": "https://finnhub.io/api/news?id=819e2b995fef2a78d1d9a608be1176eeb6975e3f90ffc8bd6d66e62a7b120924",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "Wells Fargo  analyst Nathan Treybeck   maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.",
                "category": "company",
                "datetime": 1786097490,
                "headline": "Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215"
              },
              {
                "id": 141147448,
                "url": "https://finnhub.io/api/news?id=42771496d59a56028a962cf7d3e7928c840ba00554b95a93a821fabde9142024",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/07/Portland--Or--Usa---Jan-21--2021-The-Tra.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.",
                "category": "company",
                "datetime": 1786089735,
                "headline": "Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session"
              },
              {
                "id": 141144733,
                "url": "https://finnhub.io/api/news?id=e26f47ae823ecc252f5680e158079bb8a60f3037a644a23f92ff40536cfbfebf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed Inc (RMD) delivers 9% revenue growth and 16% EPS growth in Q4 FY2026, while navigating Astral-related challenges and guiding to 5-7% core growth for FY2027.",
                "category": "company",
                "datetime": 1786079567,
                "headline": "ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ..."
              },
              {
                "id": 141143188,
                "url": "https://finnhub.io/api/news?id=07e7ea94ce7a8f216624befb92fb3e600fa186c7ba568ef257a838dec6539b5e",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "ResMed Inc. (RMD) Q4 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsSallilyn Schwartz - Chief Investor Relations OfficerMichael Farrell -...",
                "category": "company",
                "datetime": 1786053258,
                "headline": "ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript"
              },
              {
                "id": 141142416,
                "url": "https://finnhub.io/api/news?id=6f2d99ac4b464c82a818cf0692813ffcce8906c93fba111d3986dafdfc43bc5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP profit of $2.95 per share was 2% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1786052824,
                "headline": "ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops"
              },
              {
                "id": 141142417,
                "url": "https://finnhub.io/api/news?id=f9835639451fee0e6b3630315db2f0c70a6a253a6d8916bc5d7a11ff366e728e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed (RMD) delivered earnings and revenue surprises of +1.72% and +0.17%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1786052409,
                "headline": "ResMed (RMD) Q4 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141142998,
                "url": "https://finnhub.io/api/news?id=e266785fa8d8f2d00504ae73786d8ead1e0a5b1add3451405a963a5df2d9e061",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "RMD",
                "summary": "2026-08-06. The following slide deck was published by ResMed Inc.",
                "category": "company",
                "datetime": 1786051868,
                "headline": "ResMed Inc. 2026 Q4 - Results - Earnings Call Presentation"
              },
              {
                "id": 141139799,
                "url": "https://finnhub.io/api/news?id=3c4e732c0a08f2d876c2a482f4d79b93814f8d2b83bdda5964d532f85e4bc1a0",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "RMD",
                "summary": "ResMed (RMD) Q4 revenue slightly misses, EPS beats; stock dips ~2% on profit-taking despite record results and raised dividend.",
                "category": "company",
                "datetime": 1786050938,
                "headline": "ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9%"
              },
              {
                "id": 141140799,
                "url": "https://finnhub.io/api/news?id=e661e2a1607bf2ad8fcb76dbef26ff8284d18411bf61d9c0b7cc5f4dc1110ed7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95Returned $1.0 billion to shareholders through share repurchases and dividends during FY2026, an increase of more than 70% Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX:",
                "category": "company",
                "datetime": 1786046700,
                "headline": "Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026"
              },
              {
                "id": 141141984,
                "url": "https://finnhub.io/api/news?id=5ff0d18d32d01d3f09f4fc144fb8aa27a500d0047f05ed5443dde9968e6c51ad",
                "image": "",
                "source": "Benzinga",
                "related": "RMD",
                "summary": "ResMed (NYSE:RMD) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.89 by 2.08 percent. This is a 15.69 percent increase over earnings of $2.55 per share from the same period",
                "category": "company",
                "datetime": 1786032357,
                "headline": "ResMed Q4 Adj. EPS $2.95 Beats $2.89 Estimate, Sales $1.464B Beat $1.459B Estimate"
              },
              {
                "id": 141134279,
                "url": "https://finnhub.io/api/news?id=24ccbb918500a4321fa00cad22c2de330360be3abbadfb067d8963d2611deb98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Why the upcoming ResMed earnings matter ResMed (RMD) is back in focus ahead of its forthcoming earnings report, with Wall Street projecting quarterly earnings of $2.90 per share and revenue of about $1.46b for the period. See our latest analysis for ResMed. ResMed shares have climbed in recent weeks, with a 7 day share price return of 4.55% and a 90 day share price return of 8.28%. However, the year to date share price return is still down 8.49%, and the 1 year total shareholder return has...",
                "category": "company",
                "datetime": 1786022182,
                "headline": "ResMed (RMD) Faces An Earnings Test After A Rebound That Still Looks Undervalued"
              },
              {
                "id": 141125710,
                "url": "https://finnhub.io/api/news?id=908443464c6dac93d7d144bad74f909237b4d1ce507acfbe554ffe8dd66c08d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.",
                "category": "company",
                "datetime": 1785952740,
                "headline": "Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?"
              },
              {
                "id": 141125711,
                "url": "https://finnhub.io/api/news?id=86654da613505d37a72deed55f1f4b51cbc7a004fc7b41b9e6fd5f1e19cb0c5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.",
                "category": "company",
                "datetime": 1785951300,
                "headline": "INSP's 28.1% Past-Month Rally Raises a Key Question for Investors"
              },
              {
                "id": 141122934,
                "url": "https://finnhub.io/api/news?id=5ebdc3970abbb2a2338a21c3afa648199e0f3a8e8c03b36dd04d8ac65b339e0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.",
                "category": "company",
                "datetime": 1785941820,
                "headline": "What to Expect From These 2 MedTech Stocks This Earnings Season?"
              },
              {
                "id": 141122755,
                "url": "https://finnhub.io/api/news?id=679dc62b0d6341e0716993d69a4659ffa37cff052797d6fbc10f1828108e701d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
                "category": "company",
                "datetime": 1785935706,
                "headline": "Curious about ResMed (RMD) Q4 Performance? Explore Wall Street Estimates for Key Metrics"
              },
              {
                "id": 141104327,
                "url": "https://finnhub.io/api/news?id=352cc05ac2d4a26c5635f6fdf97bc1040f7f84f82a959edb3181f428a871c81d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Viemed Healthcare (VMD) delivered earnings and revenue surprises of -30.00% and +0.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785797109,
                "headline": "Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates"
              },
              {
                "id": 141103236,
                "url": "https://finnhub.io/api/news?id=124e694ad0b3e2f69b544333b87c4d5251ef48d8bf142f9f9ca9f8ba16d24cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
                "category": "company",
                "datetime": 1785788962,
                "headline": "1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky"
              },
              {
                "id": 141079192,
                "url": "https://finnhub.io/api/news?id=ba7731a4b95a73e9b539fb9155adffe31e1dea22943a4c45be8f8fa12e57990b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "RMD's Q4 results may reflect strong mask and device demand, portfolio innovation, acquisitions and digital health growth, with EPS seen rising 13.7%.",
                "category": "company",
                "datetime": 1785504720,
                "headline": "Resmed's Q4 Earnings on Deck: What's in Store for the Stock?"
              },
              {
                "id": 141078062,
                "url": "https://finnhub.io/api/news?id=eccab60418f61c40d3a156f57c0957bf7084f81ce29971339390e78da2a7b84d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
                "category": "company",
                "datetime": 1785504709,
                "headline": "3 Large-Cap Stocks to Consider Right Now"
              },
              {
                "id": 141067141,
                "url": "https://finnhub.io/api/news?id=2eba5c1a1a25c1b0f492d696ae339d2d6665a3f0234260cb85aab3bb8fd081ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785420019,
                "headline": "ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth"
              },
              {
                "id": 141065678,
                "url": "https://finnhub.io/api/news?id=627351a5866f253bd786f5ad7587b3fed6c6ee8ec3bbe68f04ebc325dd60a5ac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "Baxter (BAX) delivered earnings and revenue surprises of +55.56% and +5.95%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785414903,
                "headline": "Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 140991410,
                "url": "https://finnhub.io/api/news?id=a7d3773d8f60001c539390370a53abf66180cc30e499445d40c79aec749bde17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital.",
                "category": "company",
                "datetime": 1784791489,
                "headline": "3 Cash-Heavy Stocks to Research Further"
              },
              {
                "id": 140973578,
                "url": "https://finnhub.io/api/news?id=d1da9496c35a7b3d8bb71682a817d89804339dc66aec5bf1446d9a2e13a70166",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RMD",
                "summary": "ResMed (RMD) is expected to post strong fiscal Q4 earnings growth, helped by an 8.6% rise in sales a",
                "category": "company",
                "datetime": 1784653509,
                "headline": "ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 49,
            "discarded_article_count": 36
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.7,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.4,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.4,
            "vcp_reason": "站上MA50;Ready=N;Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1409496.6666666667,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1627490,
              "avg_vol_20": 1452890,
              "avg_vol_30": 1409496.6666666667,
              "range_pct_10": 0.12712306513745408,
              "range_pct_20": 0.1787339476448958,
              "range_pct_30": 0.1787339476448958,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1546604106903409,
              "dist_to_20d_high": 0.011253432647048305,
              "down_shrink_days": 2,
              "breakout_level_20d": 231.039993,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7112418587095667
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.4569690071791284,
              "turnoverUsdM": 293.70325204,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.6,
          "stopLevels": {
            "symbol": "US.RMD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 212.6458,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.5,
            "stop_loss_percent": 6.9,
            "take_profit_price": 251.6048,
            "target_multiplier": 2.2,
            "technical_strength": 2,
            "take_profit_percent": 10.1
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.4608172620328979,
          "stopLossPercent": 6.913938014358257,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.RMD",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 7.8971,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.46
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 113.63
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2792
    },
    "kdj": {
      "d": 82.73,
      "j": 82.76,
      "k": 82.74,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 71.97
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 3383409,
      "recentSlope": 150700.9,
      "previousSlope": 298640
    },
    "rsi": 64.65,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 220.9229,
      "position": "SAR喺價下",
      "distancePct": 3.29,
      "previousTrend": "上升"
    },
    "ma50": 206.1808,
    "macd": {
      "macd": 6.211235906091133,
      "trend": "強烈看漲",
      "signal": 5.738730995926173,
      "histogram": 0.4725049101649601
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 216.9934,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 19
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.88,
      "score": 4,
      "avgVolume": 1466550,
      "currentVolume": 1285691
    },
    "derived": {
      "ma20": 218.0105,
      "ma50": 206.1808,
      "prevClose": 230.65,
      "avgVolume10": 1577449,
      "avgVolume20": 1466550,
      "changePercent": -0.96,
      "avgVolumeForScore": 1466550
    },
    "ma_cross": {
      "ma20": 218.0105,
      "ma50": 206.1808,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 216.183,
      "prevMa50": 205.5508,
      "spreadPct": 5.74,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 200.0124,
      "upper": 236.0086,
      "position": "上半部"
    },
    "rsi_short": 55.99,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.88
    }
  }
}

Raw metrics JSON

{
  "close": 228.44,
  "volume": 1285691,
  "changePercent": -0.96
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.